Ducreux and colleagues presented preliminary results from a phase II study comparing FOLFIRI with bevacizumab versus dosemodiWed XELIRI and bevacizumab, taurine and demonstrated similar toxicity for the two regimens. In the XELIRI bevacizumab, arm rates of grade 3/4 neutropenia and diarrhea were 17 and 12%, respectively. The results of these two studies are comparable to the rates of grade 3/4 neutropenia and diarrhea noted in our study. These toxicity results compare favorably to the grade 3/4 neutropenia and diarrhea noted in a phase IV study of FOLFIRI and bevacizumab. The eYcacy results noted in our study were also comparable to those noted by Garcia Alfonso and colleagues, and by Ducreux and colleagues. In addition, the median PFS of 11.5 months from our study compares favorably with those from the Hurwitz study, the ECOG 9699 study of FOLFOX or XELOX and bevacizumab, and a phase IV study of FOLFIRI and bevacizumab. In summary, with Disufenton sodium modest dose reduction, the combination of bevacizumab, irinotecan, and capecitabine was well tolerated.
Furthermore, treatment eYcacy was not compromised since outcomes in the current study compared favorably with those from other Wrst line trials. Doxorubicin this combination may be considered another option for Wrst line therapy in patients with mCRC.Microtubules play a fundamental role in diverse cellular functions through a very complex dynamic process of polymerization and depolymerization. Hence, they have emerged as an important target for anticancer drugs. The success of the treatments with taxanes in breast cancer and in other tumor types has led to the development of new microtubule stabilizing agents as antineoplastic drugs. Among them, the epothilones are the furthest along in clinical development. Ixabepilone, the first in a new class of antimicrotubule agents, was approved in the USA and eight other countries both as a monotherapy in metastatic or locally advanced breast cancer after failure of an anthracycline, a taxane, and capecitabine, and as a combination with capecitabine for treatment HSP of metastatic or locally advanced breast cancer resistant to an anthracycline and a taxane.
Peripheral neuropathy, caused by morphologic or functional abnormalities in peripheral nerves, is a nonhematological adverse event associated with all MTSA based chemotherapies, it may be dose limiting and associated with functional impairment. The nature of PN may vary depending on the type of nerve fibers involved: sensory, motor, or autonomic. The incidence of grade 3/4 sensory PN in breast cancer patients treated with taxanes ranges from 0% to 33% and that of grade 3/4 motor neuropathy varies from 0% to 14%. The clinical assessment of neuropathy usually incorporates a careful evaluation of its onset, distribution, severity, and its impact on quality of life. Early diagnosis and management of mild to moderate symptoms are important to prevent progression. Neuropathy is graded by subjective complaints of patients and physical examinations by clinicians. The most widely used grading systems are National Cancer Institute Common Toxicity Criteria, ECOG and WHO criteria. The mechanism of MTSA induced PN is unclear. Preclinical models have demonstrated that both ixabepilone and taxanes produce a very similar neurotoxicity prof.